Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03109873 · ClinicalTrials.gov registry record · Early Phase 1
Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer
A Early Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT03109873 is a Early Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 9 participants.
The verdict
NCT03109873, a Early Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how well metformin hydrochloride works in affecting cytokines and exosomes in patients with head and neck cancer. Metformin hydrochloride may reduce the metabolic activity of cancer cells and of surrounding supportive tissues.
Interventions
- OTHER Placebo
- RADIATION External Beam Radiation Therapy
- DRUG Metformin Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-01-05 |
| Est. Completion | 2020-07-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03109873
The ClinicalTrials.gov registry entry for NCT03109873 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03109873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03109873 about?
NCT03109873 is a clinical study titled "Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer". This pilot clinical trial studies how well metformin hydrochloride works in affecting cytokines and exosomes in patients with head and neck cancer. Metformin hydrochloride may reduce the metabolic activity of cancer cells and of surrounding supportive tissues.
What is the current status of trial NCT03109873?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2017-01-05. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT03109873?
The interventions under investigation include: Placebo (OTHER), External Beam Radiation Therapy (RADIATION), Metformin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03109873?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.